Diabetes is a major public health challenge in both developed and developing countries. It
is estimated that in 2030, 643 million people will be living with diabetes. 1 About 1 in 10 …

Metformin is an oral antihyperglycemic drug widely used to treat type 2 diabetes mellitus
(T2DM), acting via indirect activation of 5′ Adenosine monophosphate-activated Protein …

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic
Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the …

While most people with diabetes have type 2 disease, a non-negligible minority develops a
secondary diabetes. Post-pancreatitis diabetes mellitus (PPDM) is an exemplar secondary …

OBJECTIVE Metformin is the first pharmacological option for treating type 2 diabetes.
However, the use of this drug is not recommended in individuals with impaired kidney …

The practical recommendations of the German Diabetes Society/Deutsche Diabetes
Gesellschaft (DDG) together with the German Society for Internal Medicine/Deutschen …

Metformin, a biguanide drug, is the most commonly used first-line medication for type 2
diabetes mellites due to its outstanding glucose-lowering ability. After oral administration of …

Intravenous (IV) contrast material is used extensively for CT and MRI scans done in
emergency departments (ED). Its use is essential to make many critical diagnoses in ED …

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive
cyst formation that ultimately leads to kidney failure in most patients. Approximately 10% of …

Metformin, the first choice drug for type 2 diabetes treatment in all stages of therapy, and one
of the most widely prescribed anti-hyperglycemic agents worldwide, represents a rare …